This study seeks to determine the economic effects of warfarin discontinuation in patients with nonvalvular atrial fibrillation.
Jack Mardekian, PhD
Advertisement
Articles by Jack Mardekian, PhD
This study developed and tested predictive models of opioid abuse using Humana commercial membership data that were subsequently tested in the Truven commercial data set.
Therapeutic and subtherapeutic doses of pregabalin were compared to ascertain differences in adherence, healthcare resource use, and cost between the cohorts.
Advertisement
Latest Updated Articles
- Therapeutic and Subtherapeutic Dosing of Pregabalin: Medication Adherence, Healthcare Resource Utilization, and Costs
Published: August 2nd 2012 | Updated:
- Understanding Predictors of Opioid Abuse: Predictive Model Development and Validation
Published: October 21st 2014 | Updated:
- Economic Outcomes of Warfarin Discontinuation Among Patients with Atrial Fibrillation
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
3
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
4
FDA Updates Boxed Warning for Cilta-Cel Following Reports of Immune Effector Cell–Associated Enterocolitis
5
